Search Results - "HORIGUCHI, Chikage Sato"
-
1
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice
Published in PloS one (24-06-2014)“…Inhibition of sodium glucose cotransporter 2 (SGLT2) has been reported as a new therapeutic strategy for treating diabetes. However, the effect of SGLT2…”
Get full text
Journal Article -
2
Nuclear hormone receptor expression in mouse kidney and renal cell lines
Published in PloS one (22-01-2014)“…Nuclear hormone receptors (NHRs) are transcription factors that regulate carbohydrate and lipid metabolism, immune responses, and inflammation. Although…”
Get full text
Journal Article -
3
Vaspin Is an Adipokine Ameliorating ER Stress in Obesity as a Ligand for Cell-Surface GRP78/MTJ-1 Complex
Published in Diabetes (New York, N.Y.) (01-11-2012)“…It is unknown whether adipokines derived from adipose tissues modulate endoplasmic reticulum (ER) stress induced in obesity. Here, we show that visceral…”
Get full text
Journal Article -
4
Activation of Liver X Receptor Inhibits Osteopontin and Ameliorates Diabetic Nephropathy
Published in Journal of the American Society of Nephrology (01-11-2012)“…Osteopontin is a proinflammatory cytokine and monocyte chemoattractant implicated in the pathogenesis of diabetic nephropathy. Synthetic agonists for liver X…”
Get full text
Journal Article -
5
Metallothionein deficiency exacerbates diabetic nephropathy in streptozotocin-induced diabetic mice
Published in American journal of physiology. Renal physiology (01-01-2014)“…Oxidative stress and inflammation play important roles in diabetic complications, including diabetic nephropathy. Metallothionein (MT) is induced in proximal…”
Get more information
Journal Article -
6
Telmisartan attenuates diabetic nephropathy by suppressing oxidative stress in db/db mice
Published in Nephron. Experimental nephrology (01-01-2012)“…Telmisartan, an angiotensin II type 1 receptor blocker, is widely used to treat hypertension and kidney diseases, including diabetic nephropathy, because of…”
Get more information
Journal Article -
7
The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO)
Published in Diabetes & vascular disease research (01-01-2013)“…Telmisartan partially activates the peroxisome proliferator-activated receptor γ (PPARγ), which may ameliorate the accumulation of visceral adipose tissues and…”
Get more information
Journal Article